Surface Modification of Gelatin Nanoparticles with Polyethylenimine as Gene Vector

Kuo, Wei-Ti; Huang, Hong-Yi; Chou, Min-Ju; Wu, Mengchao; Huang, Yi‐You

doi:10.1155/2011/646538

Cited by 21 publications

(14 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cationic gelatin, where the introduction of amine residues on the carboxyl groups increases the polymer positive charge, has been successfully employed for delivery of small interfering RNA (siRNA) [38, 50], as well as intracellular DNA [51, 52]. Several agents have been used to “cationize” gelatin, such as ethylenediamine [38, 49], polyethylenimine [50, 53], and spermine [9, 54, 55]. …”

Section: Modification Of Gelatinmentioning

confidence: 99%

Gelatin carriers for drug and cell delivery in tissue engineering

Santoro

Tatara

Mikos

2014

Journal of Controlled Release

334

202

View full text Add to dashboard Cite

The ability of gelatin to form complexes with different drugs has been investigated for controlled release applications. Gelatin parameters, such as crosslinking density and isoelectric point, have been tuned in order to optimize gelatin degradation and drug delivery kinetics. In recent years, focus has shifted away from the use of gelatin in isolation towards the modification of gelatin with functional groups and the fabrication of material composites with embedded gelatin carriers. In this review, we highlight some of the latest work being performed in these areas and comment on trends in the field. Specifically, we discuss gelatin modifications for immune system evasion, drug stabilization, and targeted delivery, as well as gelatin composite systems based on ceramics, naturally-occurring polymers, and synthetic polymers.

show abstract

Section: Modification Of Gelatinmentioning

confidence: 99%

Gelatin carriers for drug and cell delivery in tissue engineering

Santoro

Tatara

Mikos

2014

Journal of Controlled Release

334

202

View full text Add to dashboard Cite

show abstract

“…Therefore, the degree of cationic surface modification must be optimized for the enhancement of cellular internalization while avoiding excessive cytotoxicity. The surface modification of GNPs was performed with 1.8 kD PEI; 10 kDa PEI was excessively cytotoxic, whereas PEI with lower molecular weights were less cytotoxic but exhibited lower colloidal stability, which reduces electric binding efficiency . Surface modification with PEI conferred cationic properties to the GNPs, which prevented isoelectric aggregation, and thereby maintained particle size and ζ potential.…”

Section: Discussionmentioning

confidence: 99%

Surface assembly of poly(I:C) on polyethyleneimine‐modified gelatin nanoparticles as immunostimulatory carriers for mucosal antigen delivery

et al. 2018

View full text Add to dashboard Cite

The mucosal immune system is the host's first line of defense against invasion by foreign pathogens. Gelatin nanoparticles (GNPs) are suitable carriers for the delivery of antigens via various routes of administration. In the present study, GNPs were modified with polyethyleneimine (PEI), a positively charged polymer. Then, ovalbumin (OVA) and polyinosinic:polycytidylic acid (poly(I:C)), an immunostimulant, were adsorbed onto the surface of the positively charged GNPs. We assessed whether GNPs could act as an effective mucosal vaccine that is capable of inducing both mucosal and systemic immune responses. The results showed that GNPs effectively adsorbed OVA/poly(I:C), facilitated cellular uptake by RAW 264.7 macrophage cells and murine bone marrowderived dendritic cells (BMDCs) in vitro, and led to increased expression of the maturation markers CD80 and CD86 on BMDCs. Furthermore, GNPs induced increased secretion of proinflammatory cytokines in both RAW 264.7 and BMDCs. C57BL/6 mice that were intranasally twice-immunized with OVA/poly(I:C)-loaded GNPs produced high levels of serum OVA-specific IgG antibodies and secretory IgA in nasal and lung lavage. Spleen cells from immunized mice were collected and re-stimulated with OVA, and results showed significantly augmented production of IFN-γ, IL-4, IL-5, and IL-6 in mice that received OVA/poly(I:C)-loaded GNPs. Moreover, intranasal immunization with OVA/poly(I:C)-loaded GNPs resulted in the inhibition of EG7 tumor growth in C57BL/6 mice. Taken together, these results indicate that nasal administration of OVA/poly(I:C)-loaded GNPs elicited effective mucosal and systemic immune responses, which might be useful for further applications of antigen delivery.

show abstract

“…The PEGylated GNPs provide sustained drug release up to 4 days with improved bioavailability and plasma half-life compared to non-PEGylated GNPs. endosomal and lysosomal buffering capacity as "proton sponge" which can protect the nucleotides from degradation and release from the acidic vesicles [106]. Cationized GNPs also used as a sustained release vehicle for small interfering RNA (siRNA) inside the cells for gene suppression.…”

Section: Pegylated Gnpsmentioning

confidence: 99%